PRECLINICAL CHARACTERIZATION OF A NEW PASTEURIZED MONOCLONAL-ANTIBODY PURIFIED FACTOR-VIIIC

The treatment of hemophilia A patients has progressed in the last 30 years. The development of more pure factor VIII concentrates has been encouraged by the appearance of the human immunodeficiency virus in blood supply. Monoclate ® was the first essentially pure form of factor VIII available for hemophilia therapy. The liquid pasteurized form of Monoclate ® represents a new standard for therapy that attempts to eliminate a broad spectrum of viral content in factor VIII preparations.